Cargando…
Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration
Introduction: Temozolomide (TMZ) is the first-line drug for glioblastoma (GBM), but it is limited in clinical use due to the drug resistance, poor brain targeting, and side effects. Temozolomide hexadecyl ester (TMZ16e), a TMZ derivative with high lipophilicity, membrane permeability, and high anti-...
Autores principales: | Wang, Siqi, Yu, Yawen, Wang, Aiping, Duan, Xinliu, Sun, Yuchen, Wang, Liangxiao, Chu, Liuxiang, Lv, Yanan, Cui, Nan, Fan, Xuesong, Sha, Chunjie, Xu, Lixiao, Sun, Kaoxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429944/ https://www.ncbi.nlm.nih.gov/pubmed/36059989 http://dx.doi.org/10.3389/fphar.2022.965789 |
Ejemplares similares
-
Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting
por: Chu, Liuxiang, et al.
Publicado: (2018) -
Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
por: Bi, Chenchen, et al.
Publicado: (2016) -
Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease
por: Meng, Qingqing, et al.
Publicado: (2018) -
Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease
por: Tang, Shengnan, et al.
Publicado: (2019) -
Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects
por: Yan, Xiuju, et al.
Publicado: (2018)